RT Journal Article
SR Electronic
T1 Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.29.20140376
DO 10.1101/2020.06.29.20140376
A1 Meizlish, Matthew L.
A1 Pine, Alexander B.
A1 Goshua, George
A1 Chang, C-Hong
A1 Zhang, Hanming
A1 Bishai, Jason
A1 Bahel, Parveen
A1 Patel, Amisha
A1 Gbyli, Rana
A1 Kwan, Jennifer
A1 Price, Christina
A1 Dela Cruz, Charles S.
A1 Halene, Stephanie
A1 van Dijk, David
A1 Hwa, John
A1 Lee, Alfred I.
A1 Chun, Hyung J.
YR 2020
UL http://medrxiv.org/content/early/2020/07/01/2020.06.29.20140376.abstract
AB Despite over 9.3 million infected and 479,000 deaths, the pathophysiological factors that determine the wide spectrum of clinical outcomes in COVID-19 remain inadequately defined. Importantly, patients with underlying cardiovascular disease have been found to have worse clinical outcomes,1 and autopsy findings of endotheliopathy as well as angiogenesis in COVID-19 have accumulated.2,3 Nonetheless, circulating vascular markers associated with disease severity and mortality have not been reliably established. To address this limitation and better understand COVID-19 pathogenesis, we report plasma profiling of factors related to the vascular system from a series of patients admitted to Yale-New Haven Hospital with confirmed diagnosis of COVID-19 via PCR, which demonstrate significant increase in markers of angiogenesis and endotheliopathy in patients hospitalized with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported in part by the National Heart Lung Blood Institute (HL142818) to HJC and gift donation from Jack Levin to the Benign Hematology Program at Yale.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Yale University institutional review board (IRB #2000027792 and #1401013259).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A